2018-11-07T07:20:45-06:00 2017-12-31 410746749 CLIFTONLARSONALLEN LLP 901 N GLEBE ROAD SUITE 200 ARLINGTON VA 22203 990 2017-01-01 521224577 BIOTECHNOLOGY INNOVATION ORGANIZATION BIOT 2029629200 1201 MARYLAND AVENUE SW NO 900 WASHINGTON DC 20024 YVETTE WHITE-WIGGINS CFO AND SVP, FINANCE & ADMIN 2029629200 2018-10-30 1 IVY BECKHAM P01316131 5712279500 67.137.57.251 2018-10-30 00:18:05 ED P 117C9FDD72C608EEAC637569487DFDD6D3A36660 117C9FDD72C608EEAC637569487DFDD6D3A36660 2017 2019-02-21 02:37:17Z JAMES C GREENWOOD 1201 MARYLAND AVENUE SW NO 900 WASHINGTON DC 20024 83749665 0 X WWW.BIO.ORG X 1993 DC SUPPORT THE BIOTECHNOLOGY INDUSTRY TO EXPAND THE BOUNDARIES OF SCIENCE TO BENEFIT MANKIND. 113 113 208 167 713427 -31277 0 0 64830661 66032153 1712696 2716705 10372053 9803104 76915410 78551962 596583 785500 0 0 31655808 34575243 0 0 0 47122286 42956281 79374677 78317024 -2459267 234938 73322307 81025145 33540196 34368598 39782111 46656547 X THE BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) REPRESENTS APPROXIMATELY 1,000 COMPANIES AND ORGANIZATIONS IN WASHINGTON DC, STATE CAPITALS, AND INTERNATIONAL FORA. BIO IS FOUNDED ON THE PRINCIPLE THAT POLICY MUST NURTURE INNOVATION IN THE LIFE SCIENCES TO OVERCOME CHALLENGES IN HEALTH CARE, AGRICULTURE, INDUSTRY, AND THE ENVIRONMENT. OUR MEMBERS REPRESENT COMPANIES OFFERING A SPECTRUM OF BIOTECHNOLOGY APPLICATIONS ACROSS MAJOR SECTORS OF THE ECONOMY. BIO MEMBERS ALSO INCLUDE UNIVERSITIES, NONPROFITS, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT PLAY AN IMPORTANT ROLE IN THE FUTURE OF THE LIFE SCIENCES. BIO'S ACTIVITIES ARE BROKEN DOWN INTO TWO PROGRAMS - ADVOCACY AND SERVICES. 0 0 ADVOCACY: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)'S ADVOCACY EFFORTS REFLECT THE PRIORITIES IDENTIFIED BY THE BIO BOARD OF DIRECTORS AND THE FOUR SECTION GOVERNING BOARDS.THE BOARD OF DIRECTORS FOCUSES ON ISSUES OF IMPORTANCE TO ALL BIO MEMBERS, REGARDLESS OF THEIR SIZE OR TECHNOLOGY. THESE CROSS-CUTTING ADVOCACY ACCOMPLISHMENTS IN 2017 ARE LISTED BELOW: - SAFEGUARDED AND ADVANCED INTELLECTUAL PROPERTY PROTECTIONS, DOMESTICALLY AND INTERNATIONALLY.- FOSTERED A DIALOGUE ABOUT BIOETHICS AND PROACTIVELY ADVANCED THE SOCIALLY RESPONSIBLE USE OF BIOTECHNOLOGY.- PROMOTED INVESTMENT IN GOVERNMENT AND ACADEMIC RESEARCH.- PROMOTED COMPREHENSIVE REFORM OF THE U.S. TAX CODE TO SPUR INNOVATION AND INVESTMENT IN BIOTECHNOLOGY.- EXPANDED OUTREACH TO FOREIGN GOVERNMENTS AND INTERNATIONAL ENTITIES TO EDUCATE ON POLICY ISSUES OF IMPORTANCE TO THE BIOTECHNOLOGY INDUSTRY AND TO IMPROVE THE INVESTMENT AND REGULATORY CLIMATE FOR BIOTECH PRODUCTS.THE HEALTH SECTION 2017 ADVOCACY ACCOMPLISHMENTS: - ADVOCATED FOR THE PASSAGE OF THE 21ST CENTURY CURES ACT - SUCCESSFULLY FINISHED NEGOTIATIONS ON REAUTHORIZING THE PRESCRIPTION DRUG USER FEE ACT TO IMPROVE THE U.S. FOOD AND DRUG ADMINISTRATION'S (FDA'S) PROCESS FOR HUMAN DRUG REVIEW.- PROMOTED HEALTHCARE POLICIES THAT RECOGNIZE BOTH THE PROMISE AND VALUE OF INNOVATION.- ADVOCATED FOR A SAFE AND PREDICTABLE REGULATORY ENVIRONMENT FOR VALUE-BASED PAYMENT ARRANGEMENTS FOR DRUGS AND BIOLOGICS.- ENHANCED AND PROTECTED PATIENT ACCESS TO INNOVATIVE THERAPIES AND PROMOTED THE NEED FOR GREATER NONDISCRIMINATION ENFORCEMENT AGAINST INSURANCE BENEFIT DESIGNS.- ADVOCATED FOR BIOSIMILARS POLICIES THAT PROTECT PATIENT SAFETY, PROMOTE BIOMEDICAL INNOVATION, AND ADVANCE THE SCIENCE-BASED REVIEW AND APPROVAL OF BIOSIMILARS AND INTERCHANGEABLE BIOLOGICAL PRODUCTS.- PROMOTED THE VALUE OF U.S. GOVERNMENT INVESTMENTS IN PROGRAMS THAT IMPROVE ACCESS TO IMMUNIZATIONS AND FOSTER VACCINE INNOVATION, STRENGTHENED OUR ABILITY TO RESPOND TO BIOTERROR THREATS OR EMERGING INFECTIOUS DISEASES, AND ENCOURAGED DEVELOPMENT OF NEW PRODUCTS TO FIGHT ANTIMICROBIAL RESISTANCE (AMR).- INFLUENCED IMPROVEMENTS TO THE INTERNATIONAL ENVIRONMENT FOR BIOMEDICAL INNOVATION AND GLOBAL PUBLIC HEALTH PREPAREDNESS.THE EMERGING COMPANIES SECTION 2017 ADVOCACY ACCOMPLISHMENTS: - ADVANCED THE INTEREST OF EMERGING COMPANIES IN CAPITAL FORMATION AND FINANCIAL SERVICES POLICY.- ADVOCATED FOR TAX POLICIES SUPPORTING INNOVATIVE EMERGING COMPANIES AND INVESTMENT IN GROUNDBREAKING R&D; ENHANCED THE VOICE OF PRE-REVENUE, R&D-INTENSIVE BUSINESSES IN THE TAX REFORM DEBATE.- ADVOCATED FOR THE REMOVAL OF BURDENSOME FINANCIAL REPORTING REGULATIONS ON EMERGING COMPANIES.- SUPPORTED THE SEC SMALL BUSINESS ADVOCATE ACT TO ENHANCE THE ROLE OF SMALL BUSINESSES IN THE SEC'S DECISION-MAKING PROCESS, WHICH WAS SIGNED INTO LAW BY PRESIDENT OBAMA IN DECEMBER 2016.THE FOOD & AGRICULTURE SECTION 2017 ADVOCACY ACCOMPLISHMENTS: - SUCCESSFULLY ADVOCATED FOR PASSAGE OF THE NATIONAL BIOENGINEERED FOOD DISCLOSURE LAW - WORKED WITH THE ADMINISTRATION AND CONGRESS TO ADVANCE IMPROVEMENTS TO THE U.S. AND GLOBAL REGULATORY SYSTEMS FOR AG-BIOTECH PRODUCTS. - WORKED WITH MEMBERS OF THE AGRICULTURAL VALUE CHAIN TO ADDRESS TRADE ISSUES IN AGRICULTURAL EXPORT MARKETS SUCH AS CHINA AND EUROPE. - WORKED WITH AGRICULTURAL INDUSTRY ALLIES TO OPPOSE FEDERAL AND STATE-LEVEL INITIATIVES AIMED AT MANDATING GMO FOOD LABELING.- ADVOCATED IN LEGISLATURES AND COURTS TO PRESERVE THE RIGHTS OF FARMERS TO PLANT GENETICALLY ENGINEERED CROPS. THE INDUSTRIAL & ENVIRONMENTAL SECTION 2017 ADVOCACY ACCOMPLISHMENTS: - PRODUCED A RENEWABLE CHEMICALS REPORT TO CAPTURE THE BROAD SCOPE OF TECHNOLOGIES, PARTNERSHIPS, AND RAPID GROWTH OF THE RENEWABLE CHEMICALS SECTOR.- ADVOCATED FOR EPA TO TREAT ALL SUSTAINABLY SOURCED BIOMASS AS ELIGIBLE MEASURES FOR EMISSIONS REDUCTION CREDIT (ERC) GENERATION. - ADVOCATED REGARDING THE PASSAGE AND IMPLEMENTATION OF THE TOXIC SUBSTANCES CONTROL ACT (TSCA) AS AMENDED BY CONGRESS, AS WELL AS ISSUES RELATING TO THE NATIONAL BIOENGINEERED FOOD DISCLOSURE ACT.- ENGAGED WITH THE ADMINISTRATION'S REVIEW OF THE COORDINATED FRAMEWORK FOR BIOTECHNOLOGY, INCLUDING WITH RESPECT TO THE REGULATION OF GENETICALLY ENGINEERED (GE) ALGAE.- SUCCESSFULLY SECURED POSITIVE CHANGES TO EPA'S FINAL RENEWABLE FUEL STANDARDS (RFS) RULE FOR 2017. - URGED CONGRESS TO EXTEND A SUITE OF CRITICAL ADVANCED BIOFUELS TAX INCENTIVES BEYOND 2017. SERVICES: BIO'S SERVICES INCLUDE CONFERENCES AND ACTIVITIES THAT BRING TOGETHER INDUSTRY STAKEHOLDERS AND INVESTORS FOR EVENTS RANGING FROM THE BIO INTERNATIONAL CONVENTION TO CONFERENCES FOR BUSINESS DEVELOPMENT EXECUTIVES. THE BIO INTERNATIONAL CONVENTION ATTRACTS APPROXIMATELY 16,000 OF THE MOST INFLUENTIAL BIOTECH AND PHARMA ATTENDEES FROM 76 COUNTRIES AND 48 U.S. STATES, AS WELL AS THE DISTRICT OF COLUMBIA, PUERTO RICO AND THE US VIRGIN ISLANDS, INCLUDING 300 MEMBERS OF THE MEDIA, AND OFFERS THREE DAYS OF PROFESSIONAL AND BUSINESS DEVELOPMENT OPPORTUNITIES. THE NET INCOME FROM THE CONVENTION SUPPORTS OUR ADVOCACY, PUBLIC OUTREACH, AND OTHER MEMBER SERVICE ACTIVITIES. THE KEY ELEMENTS OF THE BIO INTERNATIONAL CONVENTION ARE EDUCATIONAL PROGRAMMING, EXHIBITION, THE BIO BUSINESS FORUM, AND NETWORKING EVENTS. THESE ELEMENTS PROVIDE AN OPPORTUNITY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, ACADEMIC RESEARCH INSTITUTIONS, AND INVESTORS FROM AROUND THE WORLD TO LEARN ABOUT RECENT SCIENTIFIC AND POLICY DEVELOPMENTS, AND SCHEDULE ONE-ON-ONE MEETINGS TO DISCUSS POTENTIAL BUSINESS OPPORTUNITIES. IN 2017, THE BIO BUSINESS FORUM ALONE HELPED HOST A RECORD NUMBER OF OVER 35,700 PARTNERING MEETINGS AMONG MORE THAN 3,400 COMPANIES, ALONG WITH 192 COMPANY PRESENTATIONS, OVER 800 SPEAKERS, 1,800 EXHIBITIONS WITH 50 INTERNATIONAL, REGIONAL AND STATE PAVILIONS AND SEVEN PRODUCT FOCUS ZONES.BEYOND THE CONVENTION, BIO HOSTS OR CO-HOSTS A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES THAT PROVIDE VENUES FOR MEMBER AND NON-MEMBER COMPANIES TO PRESENT NEW DATA, MEET WITH FELLOW BIOTECH COMPANIES, AND ATTRACT FUNDING FROM INVESTORS AND OTHER ORGANIZATIONS. 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 158 0 208 1 1 1 1 IN 0 0 0 0 X 113 113 0 0 0 0 1 1 0 1 1 0 0 0 1 1 1 1 1 1 1 0 X YVETTE WHITE-WIGGINS 2029629200 1201 MARYLAND AVENUE SW SUITE 990 WASHINGTON DC 20024 JOHN MARAGANORE CHAIR 2.00 X X 0 0 0 RON COHEN MD CHAIR, IMMEDIATE PAST CHAIR 2.00 X X 0 0 0 BRADFORD A ZAKES TREASURER 2.00 X X 0 0 0 JULIE GERBERDING SECRETARY 2.00 X X 0 0 0 DAVID P MEEKER SECRETARY (PARTIAL YEAR) 2.00 X X 0 0 0 ABBIE CELNIKER BOARD MEMBER 2.00 X 0 0 0 ADAM MONROE BOARD MEMBER 2.00 X 0 0 0 ADELENE PERKINS BOARD MEMBER 2.00 X 0 0 0 ALAN SHAW BOARD MEMBER 2.00 X 0 0 0 ALBERT BOURLA BOARD MEMBER 2.00 X 0 0 0 AMIR NASHAT BOARD MEMBER 2.00 X 0 0 0 ANNA RATH BOARD MEMBER 2.00 X 0 0 0 ANNE PHILLIPS BOARD MEMBER 2.00 X 0 0 0 BASSIL I DAHIYAT BOARD MEMBER 2.00 X 0 0 0 BENJAMIN R KNUDSEN BOARD MEMBER 2.00 X 0 0 0 BILL ANDERSON BOARD MEMBER 2.00 X 0 0 0 BILL SIBOLD BOARD MEMBER 2.00 X 0 0 0 BRIAN BARKER BOARD MEMBER 2.00 X 0 0 0 BRIAN THOME BOARD MEMBER 2.00 X 0 0 0 C DAVID NICHOLSON BOARD MEMBER 2.00 X 0 0 0 CARLOS PAYA BOARD MEMBER 2.00 X 0 0 0 CARSTEN BRUNN BOARD MEMBER 2.00 X 0 0 0 CHRISTI L SHAW BOARD MEMBER 2.00 X 0 0 0 CHRISTOPHER HEALEY BOARD MEMBER 2.00 X 0 0 0 CHRISTOPHER STANDLEE BOARD MEMBER 2.00 X 0 0 0 CLIVE MEANWELL BOARD MEMBER 2.00 X 0 0 0 DAN MEAGHER BOARD MEMBER 2.00 X 0 0 0 DAPHNE PREUSS BOARD MEMBER 2.00 X 0 0 0 DAVID MAIN BOARD MEMBER 2.00 X 0 0 0 DAVID STACK BOARD MEMBER 2.00 X 0 0 0 DEBORAH DUNSIRE BOARD MEMBER 2.00 X 0 0 0 DOUG BERVEN BOARD MEMBER 2.00 X 0 0 0 DOUGLAS DOERFLER BOARD MEMBER 2.00 X 0 0 0 EDDIE SULLIVAN BOARD MEMBER 2.00 X 0 0 0 ELIZABETH LEWIS BOARD MEMBER 2.00 X 0 0 0 FRANK TERHORST BOARD MEMBER 2.00 X 0 0 0 GARY ZIEZIULA BOARD MEMBER 2.00 X 0 0 0 GIL VAN BOKKELEN PHD BOARD MEMBER 2.00 X 0 0 0 GOERGE A SCANGOS BOARD MEMBER 2.00 X 0 0 0 H THOMAS WATKINS BOARD MEMBER 2.00 X 0 0 0 HELEN TORLEY BOARD MEMBER 2.00 X 0 0 0 HERVE HOPPENOT BOARD MEMBER 2.00 X 0 0 0 HOWARD ROBIN BOARD MEMBER 2.00 X 0 0 0 HUGH C WELSH JD BOARD MEMBER 2.00 X 0 0 0 JAMES SAPIRSTEIN BOARD MEMBER 2.00 X 0 0 0 JAMES SULLIVAN BOARD MEMBER 2.00 X 0 0 0 JEAN-CHRISTOPHE TELLIER BOARD MEMBER 2.00 X 0 0 0 JEAN-JACQUES BIENAIME BOARD MEMBER 2.00 X 0 0 0 JEFF KINDLER BOARD MEMBER 2.00 X 0 0 0 JEFFREY CLELAND BOARD MEMBER 2.00 X 0 0 0 JEFFREY MARRAZZO BOARD MEMBER 2.00 X 0 0 0 JENNIFER HOLMGREN BOARD MEMBER 2.00 X 0 0 0 JENNIFER TAUBERT BOARD MEMBER 2.00 X 0 0 0 JEREMY LEVIN BOARD MEMBER 2.00 X 0 0 0 JERRY FLINT BOARD MEMBER 2.00 X 0 0 0 JIM MEYERS BOARD MEMBER 2.00 X 0 0 0 JOEL MARCUS BOARD MEMBER 2.00 X 0 0 0 JOHN CROWLEY BOARD MEMBER 2.00 X 0 0 0 JOHN LEPORE BOARD MEMBER 2.00 X 0 0 0 JOHN MELO BOARD MEMBER 2.00 X 0 0 0 JOHN SWART BOARD MEMBER 2.00 X 0 0 0 JOSEPH LAROSA BOARD MEMBER 2.00 X 0 0 0 JOSHUA OFMAN BOARD MEMBER 2.00 X 0 0 0 KATRINE BOSLEY BOARD MEMBER 2.00 X 0 0 0 KENNETH MOCH BOARD MEMBER 2.00 X 0 0 0 KIRAN MAZUMDAR-SHAW BOARD MEMBER 2.00 X 0 0 0 LAURA BEREZIN BOARD MEMBER 2.00 X 0 0 0 LONNIE MOULDER BOARD MEMBER 2.00 X 0 0 0 MARK DROZDOWSKI BOARD MEMBER 2.00 X 0 0 0 MARK ENYEDY BOARD MEMBER 2.00 X 0 0 0 MARK JONES BOARD MEMBER 2.00 X 0 0 0 MARK PRUZANSKI BOARD MEMBER 2.00 X 0 0 0 MARK SKALETSKY BOARD MEMBER 2.00 X 0 0 0 MARK TRUDEAU BOARD MEMBER 2.00 X 0 0 0 MARTIN BABLER BOARD MEMBER 2.00 X 0 0 0 MAXINE GOWEN BOARD MEMBER 2.00 X 0 0 0 MICHAEL MORRISSEY BOARD MEMBER 2.00 X 0 0 0 MICHAEL NARACHI BOARD MEMBER 2.00 X 0 0 0 MICHAEL RAAB BOARD MEMBER 2.00 X 0 0 0 MICHAEL RYAN BOARD MEMBER 2.00 X 0 0 0 NANCY SIMONIAN BOARD MEMBER 2.00 X 0 0 0 NICK LESCHLY BOARD MEMBER 2.00 X 0 0 0 PAUL BACKMAN BOARD MEMBER 2.00 X 0 0 0 PAUL HASTINGS BOARD MEMBER 2.00 X 0 0 0 PAUL MCKENZIE BOARD MEMBER 2.00 X 0 0 0 PERRY STERNBERG BOARD MEMBER 2.00 X 0 0 0 PETER GREENLEAF BOARD MEMBER 2.00 X 0 0 0 PHILIP MILLER BOARD MEMBER 2.00 X 0 0 0 RACHEL KING BOARD MEMBER 2.00 X 0 0 0 RICHARD POPS BOARD MEMBER 2.00 X 0 0 0 RICK WINNINGHAM BOARD MEMBER 2.00 X 0 0 0 ROBERT WILLS BOARD MEMBER 2.00 X 0 0 0 ROGER WYSE BOARD MEMBER 2.00 X 0 0 0 RONALD STOTISH BOARD MEMBER 2.00 X 0 0 0 RUSSELL HERNDON BOARD MEMBER 2.00 X 0 0 0 SABINE LUIK BOARD MEMBER 2.00 X 0 0 0 SANDY MACRAE BOARD MEMBER 2.00 X 0 0 0 SCOTT GARLAND BOARD MEMBER 2.00 X 0 0 0 SCOTT HOLMSTROM BOARD MEMBER 2.00 X 0 0 0 SCOTT KOENIG BOARD MEMBER 2.00 X 0 0 0 SCOTT SMITH BOARD MEMBER 2.00 X 0 0 0 SHAJ PROCIDA BOARD MEMBER 2.00 X 0 0 0 SIMON WADDINGTON BOARD MEMBER 2.00 X 0 0 0 STEVEN MENTO BOARD MEMBER 2.00 X 0 0 0 STEVEN PAUL BOARD MEMBER 2.00 X 0 0 0 STUART A ARBUCKLE BOARD MEMBER 2.00 X 0 0 0 TAMMY LEE STANOCH BOARD MEMBER 2.00 X 0 0 0 TED W LOVE BOARD MEMBER 2.00 X 0 0 0 THOMAS WIGGANS BOARD MEMBER 2.00 X 0 0 0 TIMOTHY P WALBERT BOARD MEMBER 2.00 X 0 0 0 TJERK DE RUITER BOARD MEMBER 2.00 X 0 0 0 VINCENT SEWALT BOARD MEMBER 2.00 X 0 0 0 WILLIAM FITZSIMMONS BOARD MEMBER 2.00 X 0 0 0 WILLIAM NEWELL BOARD MEMBER 2.00 X 0 0 0 ALEX AZAR BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 ALLEN WAXMAN BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 CHRISTIAN NOLET BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 CHRISTOPH WESTPHAL BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 CHRISTOPHER BOERNER BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 CRAIG LANDAU BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 ELI BEN-SHOSHAN BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 EMIL KAKKIS BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 GARY PHILLIPS BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 GLENN GORMLEY BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 HAROLD E VAN WART PHD BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 HENRI A TERMEER BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JAMES HEALY BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JAMES LEVINE BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JAY SIEGEL BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JEAN-FRANCOIS FORMELA BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JOHN MENDLEIN BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JOHN ORWIN BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JONATHAN LEFF BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JONATHAN WOLFSON BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JOSEPH SHAULSON BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 KATHLEEN TREGONING BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 MARK ALLES BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 MARK TIMNEY BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 MARKUS POMPEJUS BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 MICHAEL KNUTZEN BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 MICHELLE DIPP BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 MONCEF SLAOUI BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 NEIL GOLDSMITH BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 NEIL K WARMA BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 PAUL EISENBERG BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 PERRY KARSEN BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 ROBERT REPELLA BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 THOMAS MATHERS BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 WILLIAM HINSHAW BOARD MEMBER (PARTIAL YEAR) 2.00 X 0 0 0 JAMES C GREENWOOD PRESIDENT & CHIEF EXECUTIVE OFFICER 40.00 X 4382224 0 888749 YVETTE WHITE-WIGGINS SVP & CHIEF FINANCIAL OFFICER 40.00 X 404050 0 70851 THOMAS DILENGE PRESIDENT, ADVOCACY/LAW/PUBLIC POLICY DIV 40.00 X 701370 0 71486 JOANNE DUNCAN PRESIDENT, MEMBERSHIP & BUS OPER DIV 40.00 X 701370 0 66932 BRENT ERICKSON EVP, INDUSTRIAL & ENVIRONMENT 40.00 X 518015 0 55320 DANIEL DURHAM EVP, HEALTH POLICY 40.00 X 579487 0 69241 ELIZABETH ESHAM EVP, ECS & VP, SCIENCE & REGULATORY 40.00 X 429503 0 50968 JOSEPH DAMOND SVP, INTERNATIONAL AFFAIRS 40.00 X 480493 0 72041 KATHLEEN HOLCOMBE SVP, SCIENCE POLICY (PARTIAL YEAR) 40.00 X 434445 0 9150 8630957 0 1354738 95 0 1 0 FREEMAN EXPOSITIONS PO BOX 660613 DALLAS TX 75266 CONVENTION & CONFERENCES GENERAL CONTRAC 2289565 CENTERPLATE 111 WEST HARBOR DRIVE SAN DIEGO CA 92101 CATERING 1096032 WHITE64 8603 WESTWOOD CENTER DRIVE 4TH FLO TYSONS VA 22182 COMMUNICATION SERVICES 934546 PROJECTION INC PO BOX 890472 CHARLOTTE NC 28289 AV 873243 SAN DIEGO PADRES 100 PARK BOULEVARD SAN DIEGO CA 92101 CONVENTION RECEPTION 643492 91 CONFERENCE/MEETING REVENUE 541800 36155018 35861488 293530 MEMBERSHIP DUES 900099 28470916 28470916 EPF MEMBER SUPPORT 900099 900000 900000 INTERNATIONAL EFFORTS 900099 336500 336500 LEGAL & POLICY SUPPORT 900099 169719 169719 66032153 1771610 1771610 9616356 384654 9231702 40244 40244 0 6102554 5157459 945095 945095 945095 CBI 900099 119706 119706 BIONEWS ADS INCOME 541800 32072 32072 JOB BOARD 900004 3171 3171 31799 31799 186748 78551962 65858329 713427 11980206 X 785500 7287032 21478885 1218651 3088672 1502003 355633 70894 3176909 55567 8535085 365565 692979 1436486 4111480 1621449 16110899 2371 3703359 630358 120496 DUES & SUBSCRIPTIONS 1334958 OUTREACH 347499 TAXES PAID 83896 BAD DEBT EXPENSE 10000 190398 78317024 5985669 6917248 2007963 3265043 3650322 3137266 2073003 2686112 10206512 9264135 1572895 942377 58032455 64077099 73322307 81025145 17667769 17217909 11510981 13458572 4361446 3692117 33540196 34368598 X 39782111 46656547 39782111 46656547 73322307 81025145 234938 6639498 0 X 0 1 X 1 0 0 0 1 28470916 10223685 -566403 9657282 9395402 261880 6183755 5495611 688144 788262 785668 2594 3234495 2982856 251639 942377 CAPITAL LEASE OBLIGATION 2518 DEFERRED RENT 3689599 3692117 88228246 6639498 3052109 9691607 78536639 55567 -40244 15323 78551962 81353810 3092353 3092353 78261457 55567 55567 78317024 PART XI, LINE 2D - OTHER ADJUSTMENTS: FOOD & AG SGR FUND 2,540,774. FOOD & AG LEGAL FUND 11,992. BIOSIMILARS REVENUE 439,343. FGR SPECIAL INITIATIVES REVENUE 60,000. PART XI, LINE 4B - OTHER ADJUSTMENTS: RENTAL EXPENSES -40,244. PART XII, LINE 2D - OTHER ADJUSTMENTS: FOOD & AG LEGAL FUND EXPENSES 11,992. BIOSIMILAR EXPENSES 439,343. FGR SPECIAL INITIATIVE EXPENSES 60,000. FOOD & AG SGR FUND 2,540,774. RENTAL EXPENSES 40,244. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 2 PROGRAM SERVICES CONFERENCES, ADVOCACY 388931 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 2 PROGRAM SERVICES CONFERENCES, ADVOCACY AND EDUCATION 252030 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES ADVOCACY 13391 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES CONFERENCES, ADVOCACY 828561 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 1 PROGRAM SERVICES ADVOCACY 55507 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES ADVOCACY 64533 0 5 0 0 0 5 1602953 0 1602953 0 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS SUPPORTING DOCUMENTATION FOR THE AMOUNT THAT IS INVOICED FROM THE COMPANIES. 1 ALLIANCE FOR AGING RESEARCH 1700 K STREET NW SUITE 740 WASHINGTON DC 20006 541379174 501(C)(3) 15000 SPONSORSHIP AMERICAN CANCER SOCIETY ACTION NETWORK INC 555 11TH STREET SUITE 300 WASHINGTON DC 20004 522340031 501(C)(4) 40000 SPONSORSHIP AMERICAN ENTERPRISE INSTITUTE FOR PUBLIC POLICY RESEARCH 1789 MASSACHUSETTS AVENUE NW WASHINGTON DC 20036 530218495 501(C)(3) 15000 SPONSORSHIP BIO NEBRASKA LIFE SCIENSES ASSOCIATION PO BOX 24802 OMAHA NE 68124 202214508 501(C)(6) 6000 SPONSORSHIP BIO OHIO 1275 KINNGAR ROAD COLUMBUS OH 43212 341577705 501(C)(6) 6000 SPONSORSHIP BIOCENTURY PUBLICATIONS 1235 RADIO ROAD SUITE 100 REDWOOD CITY CA 94065 943164558 N/A 15000 SPONSORSHIP BIOTECH COUNCIL OF NEW JERSEY 1255 WHITEHORSE-MERCERVILLE ROAD BLDG B SUITE 514 TRENTON NJ 08619 223284393 501(C)(6) 10000 SPONSORSHIP CANCER SUPPORT COMMUNITY 734 15TH STREET NW SUITE 300 WASHINGTON DC 20005 954163931 501(C)(3) 10000 SPONSORSHIP CHAMBER OF COMMERCE OF THE USA 1615 H STREET NW WASHINGTON DC 20062 530045720 501(C)(6) 60000 GENERAL SUPPORT COLORADO BIOSCIENCE ASSOCIATION 600 GRANT STREET NO 306 DENVER CO 80203 841363258 501(C)(6) 7500 SPONSORSHIP EVERYLIFE FOUNDATION FOR RARE DISEASES 77 DIGITAL DRIVE SUITE 210 NOVATO CA 94949 264614274 501(C)(3) 10000 SPONSORSHIP FAEGRE BAKER DANIELS 75 REMITTANCE DRIVE DEPT 6952 CHICAGO IL 606756952 410244008 N/A 10000 CONTRIBUTION FISHER HOUSE FOUNDATION INC 12300 TWINBROOK PARKWAY SUITE 410 ROCKVILLE MD 20852 113158401 501(C)(3) 15000 CONTRIBUTION FUELSAMERICA 607 FORT WILLIAMS PARKWAY ALEXANDRIA VA 22304 460991009 501(C)(4) 250000 GENERAL SUPPORT GALIEN FOUNDATION 99 JOHN STREET SUITE 2502 NEW YORK NY 10038 264549935 501(C)(3) 15000 SPONSORSHIP GEORGIA BIO 999 PEACHTREE STREET NE ATLANTA GA 30307 581849665 501(C)(6) 7500 SPONSORSHIP GLOBAL GENES 28 ARGONAUT SUITE 150 ALISO VIEJO CA 92656 263331487 501(C)(3) 10000 SPONSORSHIP HUDSON INSTITUTE 1201 PENNSYLVANIA AVENUE NW SUITE 400 WASHINGTON DC 20004 131945157 501(C)(3) 50000 GENERAL SUPPORT KEYSTONE CENTER 1628 SAINT JOHN ROAD KEYSTONE CO 80435 840688506 501(C)(3) 10000 SPONSORSHIP LEUKEMIA & LYMPHOMA SOCIETY INC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 135644916 501(C)(3) 10000 SPONSORSHIP LIFE SCIENCE PENNSYLVANIA 650 EAST SWEDESFORD ROAD NO 190 WAYNE PA 19087 251621500 501(C)(6) 22000 SPONSORSHIP LYCHEE GROUP LLC 5 CREST FRUIT COURT MANALAPAN NJ 07726 262070716 N/A 10000 SPONSORSHIP MD TECHNOLOGY COUNCIL 9841 WASHINGTONIAN BOULEVARD GAITHERSBURG MD 20878 204950778 501(C)(6) 7500 SPONSORSHIP MEDMATES INC 24 CORLISS STREET 42240 PROVIDENCE RI 02904 462858053 501(C)(6) 6000 SPONSORSHIP NATIONAL COALITION FOR CANCER SURVIVORSHIP 8455 COLESVILLE ROAD SUITE 930 SILVER SPRING MD 20910 850357897 501(C)(3) 10000 SPONSORSHIP NATIONAL HEALTH COUNCIL 1730 M STREET NW SUITE 500 WASHINGTON DC 200364561 131624107 501(C)(3) 25000 SPONSORSHIP NEHI ONE BROADWAY 15TH FLOOR BOSTON MA 02142 010624865 501(C)(3) 15000 SPONSORSHIP NO LABELS 1130 CONNECTICUT AVE NW SUITE 325 WASHINGTON DC 20036 271432208 501(C)(4) 25000 CONTRIBUTION NUS AMERICA FOUNDATION 440 NORTH WOLFE ROAD SUNNYVALE CA 94085 202368621 501(C)(3) 15000 GENERAL SUPPORT OREGON BIOSCIENCE 2828 SW CARBETT AVENUE SUITE 115 PORTLAND OR 97201 931009329 501(C)(6) 10000 SPONSORSHIP PARENT PROJECT FOR MUSCULAR DYSTROPHY RESEARCH INC 401 HACKENSACK AVENUE 9TH FLOOR HACKENSACK NJ 07601 311405490 501(C)(3) 12000 SPONSORSHIP PHARMACEUTICAL RESEARCH AND MANUFACTURES OF AMERICA 950 F STREET NW SUITE 300 WASHINGTON DC 20004 530241211 501(C)(6) 5500 GENERAL SUPPORT PREVENT CANCER FOUNDATION 1600 DUKE STREET SUITE 500 ALEXANDRIA VA 22314 521429544 501(C)(3) 14000 SPONSORSHIP RESEARCHAMERICA 241 18TH STREET SOUTH SUITE 501 ARLINGTON VA 22202 521609875 501(C)(3) 10000 SPONSORSHIP SOCIETY FOR WOMEN'S HEALTH RESEARCH 1025 CONNECTICUT AVENUE NW SUITE 601 WASHINGTON DC 20036 521694732 501(C)(3) 10000 SPONSORSHIP VIRGINIA TECH FOUNDATION INC 902 PRICES FORK ROAD SUITE 4000 BLACKSBURG VA 24061 540721690 501(C)(3) 6500 SPONSORSHIP WASHINGTON LEGAL FOUNDATION 2009 MASSACHUSETTS AVENUE NW WASHINGTON DC 20036 521071570 501(C)(3) 10000 CONTRIBUTION 20 17 PART I, LINE 2: BIO RELIES ON THE REQUIRED QUALIFICATIONS OF THE GRANT RECIPIENTS TO PROVIDE ASSURANCE OF PROPER USAGE. IN SOME CASES, BIO PERSONNEL ATTEND EVENTS AND RECEIVE ACKNOWLEDGEMENTS RELATED TO THE FUNDS GRANTED. X X X X 0 1 X X X X X 0 1 0 JAMES C GREENWOOD PRESIDENT & CHIEF EXECUTIVE OFFICER 3395824 0 940800 0 45600 0 812149 0 76600 0 5270973 0 0 0 YVETTE WHITE-WIGGINS SVP & CHIEF FINANCIAL OFFICER 303250 0 100800 0 0 0 36000 0 34851 0 474901 0 0 0 THOMAS DILENGE PRESIDENT, ADVOCACY/LAW/PUBLIC POLIC 470557 0 230813 0 0 0 36000 0 35486 0 772856 0 0 0 JOANNE DUNCAN PRESIDENT, MEMBERSHIP & BUS OPER DIV 470557 0 230813 0 0 0 36000 0 30932 0 768302 0 0 0 BRENT ERICKSON EVP, INDUSTRIAL & ENVIRONMENT 390363 0 127652 0 0 0 36000 0 19320 0 573335 0 0 0 DANIEL DURHAM EVP, HEALTH POLICY 436687 0 142800 0 0 0 36000 0 33241 0 648728 0 0 0 ELIZABETH ESHAM EVP, ECS & VP, SCIENCE & REGULATORY 323663 0 105840 0 0 0 36000 0 14968 0 480471 0 0 0 JOSEPH DAMOND SVP, INTERNATIONAL AFFAIRS 362088 0 118405 0 0 0 36000 0 36041 0 552534 0 0 0 KATHLEEN HOLCOMBE SVP, SCIENCE POLICY (PARTIAL YEAR) 340555 0 93890 0 0 0 7226 0 1924 0 443595 0 0 0 PART I, LINE 1A JAMES GREENWOOD: - NOT INCLUDED IN TAXABLE COMPENSATION TO THE INDIVIDUAL: - FIRST CLASS OR CHARTER TRAVEL - $4,026 - HEALTH OR SOCIAL CLUB DUES OR INITIATION FEES - $5,000 - INCLUDED IN TAXABLE COMPENSATION TO THE INDIVIDUAL: - TRAVEL FOR COMPANIONS - $1,149 PART I, LINE 1B THE CHIEF EXECUTIVE OFFICER HAS A PREPAID SPENDING ACCOUNT AT A LOCAL RESTAURANT, USED EXCLUSIVELY FOR BUSINESS PURPOSES. PART I, LINE 4B JAMES GREENWOOD - 457(F) $1,940,470 LAURA GREENWOOD DAUGHTER OF CEO 71553 PAID EMPLOYEE OF ORGANIZATION 0 LILY DOEFLER DAUGHTER OF A BOARD MEMBER 33944 PAID EMPLOYEE OF ORGANIZATION 0 FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS SHALL DESIGNATE BY RESOLUTION AND WITH A QUORUM PRESENT, NOT MORE THAN NINETEEN (19) DIRECTORS OF THE BOARD TO ACT AS AN EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL CONSIST OF THE SEVEN (7) ELECTED OFFICERS OF THE ORGANIZATION; THE IMMEDIATE PAST CHAIR OF THE ORGANIZATION; THE VICE CHAIRS OF EACH SECTION'S GOVERNING BOARD; AND THE BALANCE BEING AT-LARGE DIRECTORS FROM THE FULL BOARD. IF THE IMMEDIATE PAST CHAIR IS NO LONGER ELIGIBLE TO SERVE ON THE FULL BOARD, AN ADDITIONAL AT-LARGE DIRECTOR FROM THE FULL BOARD SHALL BE SELECTED FOR THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE SHALL HAVE, AND BE AUTHORIZED TO EXERCISE, ALL POWERS OF THE FULL BOARD, EXCEPT: (A) THE POWER TO ELECT OR REMOVE ELECTED OFFICERS OR DIRECTORS, TO CHANGE THE SIZE OF THE BOARD, TO CHANGE ELIGIBILITY, QUALIFICATIONS OR RIGHTS OF MEMBERSHIP, TO APPROVE THE FINANCIAL BUDGET FOR THE ORGANIZATION (THIS BUDGET LIMITATION WAS REMOVED AT THE END OF 2017 BY A BYLAW CHANGE), OR TO MAKE DETERMINATIONS AS TO DIRECTOR AND OFFICER COMPENSATION, WHERE APPLICABLE; AND (B) THE POWER TO AMEND THE ARTICLES OF INCORPORATION OR THE BYLAWS OF THE ORGANIZATION. AT THE DECEMBER 6, 2017, MEETING OF THE BIO FULL BOARD OF DIRECTORS, THE BOARD CONSIDERED AND APPROVED PROPOSED AMENDMENTS TO THE ORGANIZATION'S BYLAWS, WHICH ALLOW THE EXECUTIVE COMMITTEE (INSTEAD OF THE BOARD) TO APPROVE THE ORGANIZATION'S ANNUAL BUDGET. UPON MOTION, MOVED AND SECONDED, THE RESOLUTION TO AMEND THE BYLAWS, AND THE ACCOMPANYING PROPOSAL TO CHANGE THE GOVERNANCE AND STRATEGIC PLANNING PROCESS, WERE APPROVED WITHOUT OBJECTION, AS PRESENTED. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBERS OF THE ORGANIZATION SHALL BE DIVIDED INTO FOUR CLASSES; CORE MEMBERS, ASSOCIATE MEMBERS, AFFILIATE MEMBERS, AND CENTER MEMBERS, DEFINED AS FOLLOWS: (A) CORE MEMBERS: ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PERCENTAGE OF WHOSE BUSINESS ACTIVITIES INVOLVE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR RELATED NEW TECHNOLOGIES, IS ELIGIBLE FOR MEMBERSHIP. CORE MEMBERS ARE THOSE ENTITIES THAT UTILIZE BIOTECHNOLOGY, GENOMICS, BIOINFORMATICS OR OTHER RELATED NEW TECHNOLOGIES IN RESEARCH, DEVELOPMENT, TESTING, MANUFACTURING, OR SALES OF PRODUCT OR INFORMATION, AS WELL AS OTHER FIRMS THE BOARD SO CHARACTERIZES AND PLACES IN THIS CATEGORY. CORE MEMBERS SHALL BE GROUPED IN THE FOLLOWING SUBCATEGORIES: (I) EMERGING COMPANIES, WHICH ARE FIRMS THAT EMPLOY LESS THAN 350 PERSONS AND THAT DO NOT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; (II) ESTABLISHED FIRMS, WHICH ARE THOSE FIRMS THAT EMPLOY 350 OR MORE PERSONS OR THAT HAVE A THERAPEUTIC OR DIAGNOSTIC PRODUCT APPROVED FOR SALE IN THE U.S. MARKET; AND (III) LARGE FIRMS, WHICH ARE ESTABLISHED FIRMS THAT HAVE ANNUAL WORLDWIDE SALES OF BIOTECHNOLOGY PRODUCTS IN EXCESS OF $1.5 BILLION; AND (IV) NON-DOMESTIC COMPANIES, WHICH ARE CORE MEMBERS WITHOUT SIGNIFICANT OPERATIONS IN THE UNITED STATES OR SIGNIFICANT COLLABORATIONS WITH A U.S. ENTITY. (B) ASSOCIATE MEMBERS: ANY CORPORATION, PARTNERSHIP, ASSOCIATION, OR OTHER ENTITY ORGANIZED FOR PROFIT, A SUBSTANTIAL PORTION OF WHOSE ACTIVITIES INVOLVE PROVIDING SERVICES OR PRODUCTS OF BENEFIT TO COMPANIES WHOSE PRINCIPAL BUSINESS IS BIOTECHNOLOGY, IS ELIGIBLE FOR ASSOCIATE MEMBERSHIP. ASSOCIATE MEMBERS ARE THOSE COMMERCIAL ENTITIES WHICH DO NOT NECESSARILY UTILIZE BIOTECHNOLOGY; E.G. TECHNICAL SUPPORT, EQUIPMENT, CONSTRUCTION, ACCOUNTING, AND LAW FIRMS THAT SERVICE THE BIOTECHNOLOGY INDUSTRY, AS WELL AS OTHER FIRMS THAT THE BOARD CHARACTERIZES AND PLACES IN THIS CATEGORY. (C) AFFILIATE MEMBERS: ANY GOVERNMENTAL OR NONPROFIT ENTITY OR COUNTRY, STATE OR REGIONAL INDUSTRY, TRADE OR PROFESSIONAL ASSOCIATION WITH AN INTEREST IN, OR A MANDATE TO PROMOTE THE DEVELOPMENT OF, BIOTECHNOLOGY IS ELIGIBLE FOR AFFILIATE MEMBERSHIP. THERE SHALL BE NO SIZE TESTS APPLIED TO AFFILIATE MEMBER APPLICANTS. (D) CENTER MEMBERS: ANY INSTITUTION, NOT GENERALLY ELIGIBLE FOR CORE MEMBERSHIP THAT IS SPONSORED BY A STATE, REGION, OR ACADEMIC INSTITUTION AND WORKS IN SUPPORT OF COMMERCIAL BIOTECHNOLOGY MAY BE ELIGIBLE FOR CONSIDERATION AS A CENTER MEMBER. FORM 990, PART VI, SECTION A, LINE 7A AT ALL MEMBERSHIP MEETINGS OF THE ORGANIZATION, EACH CURRENT MEMBER SHALL HAVE ONE (1) VOTE AND MAY TAKE PART IN THE VOTING IN PERSON OR BY PROXY. FOR EACH SECTION IN WHICH THE MEMBER PARTICIPATES, EACH MEMBER SHALL HAVE THE RIGHT TO VOTE ON THE ELECTION OF DIRECTORS FOR THE SECTION GOVERNING BOARD, BUT SHALL HAVE NO OTHER VOTING RIGHTS EXCEPT ON MATTERS BROUGHT TO THE MEMBERSHIP BY ANY SUCH GOVERNING BOARD OR THE ORGANIZATION'S BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 AND RELATED SCHEDULES ARE PREPARED BY THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS UNDER THE GUIDANCE OF THE CHIEF FINANCIAL OFFICER (CFO). THE CFO AND THE CONTROLLER THOROUGHLY REVIEW ALL CALCULATIONS AND SCHEDULES TO CONFIRM THEY REFLECT THE ACTUAL FINANCIAL RESULTS OF THE ORGANIZATION. THE COMPLETE FORM 990 IS THEN REVIEWED INTERNALLY BY THE CEO, DIVISION PRESIDENTS, CFO, AND CONTROLLER IN CONSULTATION WITH LEGAL COUNSEL AND, AS APPROPRIATE, FURTHER CONSULTATION WITH THE ORGANIZATION'S CERTIFIED PUBLIC ACCOUNTANTS. FINALLY, THE FORM 990 IS PROVIDED TO THE CHAIRMAN OF THE BOARD AND BIO EXECUTIVE COMMITTEE MEMBERS FOR THEIR REVIEW, QUESTIONS AND/OR COMMENTS. ALL REVIEWS ARE COMPLETED BEFORE THE FORM IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) TAKES SEVERAL STEPS TO ADDRESS COMPLIANCE BY EMPLOYEES AND DIRECTORS WITH ITS CONFLICTS OF INTEREST POLICY. BIO TRAINS ALL NEW EMPLOYEES AND DIRECTORS ON VARIOUS ASPECTS OF BIO'S COMPLIANCE PROGRAM, INCLUDING CONFLICTS OF INTEREST, AND BIO'S WRITTEN CONFLICTS OF INTEREST POLICY REQUIRES ALL EMPLOYEES TO DISCLOSE ANY OUTSIDE PERSONAL BUSINESS INTERESTS TO THEIR SUPERVISOR. BIO'S GENERAL COUNSEL REGULARLY ADVISES BIO'S EXECUTIVES AND SUPERVISORS ON SUCH MATTERS. BIO ALSO CONTRACTS WITH AN INDEPENDENT ORGANIZATION TO PROVIDE EMPLOYEES AND OTHERS WITH THE ABILITY TO FILE ANONYMOUS REPORTS CONCERNING THE VIOLATION OF ANY LAWS OR BIO POLICIES, INCLUDING ALLEGATIONS OF POTENTIAL CONFLICTS OF INTEREST, AND BIO HAS A PROCESS IN PLACE TO FOLLOW UP ON ANY SUCH COMPLAINTS IN A TIMELY AND THOROUGH MANNER. FURTHER, BIO UNDERTAKES A QUESTIONNAIRE SENT TO EACH DIRECTOR ON ITS BOARD OF DIRECTORS SEEKING DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTERESTS THEY MAY HAVE, OR THEIR FAMILY MEMBERS MAY HAVE, ASSOCIATED WITH BUSINESSES OR ORGANIZATIONS THAT DO BUSINESS WITH BIO. POTENTIAL CONFLICTS ARE MONITORED AND REVIEWED AT THE MANAGEMENT AND SENIOR MANAGEMENT LEVEL OF THE ORGANIZATION, AND DEPENDING ON THE CONFLICT, DETERMINATIONS MAY BE MADE AT THE BOARD OR SENIOR MANAGEMENT LEVEL. A CONFLICT AT THE BOARD LEVEL WILL NORMALLY RESULT IN RECUSAL OF THE INDIVIDUAL FROM PARTICIPATION OR ACTIVITIES WITH RESPECT TO THE RELEVANT SUBJECT MATTER. AT THE STAFF LEVEL, THE APPLICABLE BIO SUPERVISOR IS INFORMED OF THE POTENTIAL CONFLICT AND IS REQUIRED TO TAKE ALL APPROPRIATE STEPS TO ENSURE THAT THE INDIVIDUAL DOES NOT PARTICIPATE IN, OR RECEIVE CONFIDENTIAL INFORMATION RELATING TO, ANY BIO ACTIVITY RELATED TO THE SUBJECT MATTER OF THE CONFLICT, UP TO AND INCLUDING, WHERE APPROPRIATE, TERMINATION OF SUCH EMPLOYEE. FORM 990, PART VI, SECTION B, LINE 15 FOR 2017, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER (CEO) OF BIO WAS COMPENSATED PER THE TERMS OF A MULTI-YEAR CONTRACT THAT WAS DETERMINED WITH INDEPENDENT REVIEW, COMPARABILITY DATA, AND CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISION AS INDICATED IN PRIOR FORM 990 SUBMISSIONS. IN ADDITION, BASED ON THE EXECUTIVE COMMITTEE'S EVALUATION OF THE PRESIDENT AND CEO'S PERFORMANCE FOR 2017, THE COMMITTEE DETERMINED THE APPROPRIATE AMOUNT FOR THE DISCRETIONARY COMPONENT OF HIS COMPENSATION FOR THAT YEAR, IN ACCORDANCE WITH THE RELEVANT PROVISION OF THE EXECUTIVE AGREEMENT. DECISIONS REGARDING THE COMPENSATION FOR OFFICERS AND KEY EMPLOYEES OF THE ORGANIZATION ARE NEGOTIATED INDIVIDUALLY AND ARE PERFORMANCE-BASED, IN ACCORDANCE WITH AN ANNUAL WRITTEN EVALUATION PROCESS THAT HAS BEEN ESTABLISHED FOR ALL EMPLOYEES OF THE ORGANIZATION. THE PRESIDENTS OF THE TWO DIVISIONS AT BIO LED THE PROCESS, IN COORDINATION WITH THE PRESIDENT & CEO. AN INDEPENDENT CONSULTANT PROVIDES COMPARATIVE BENCHMARKING SERVICES FOR SENIOR MANAGEMENT POSITIONS, AND OTHER INFORMATION ON COMPENSATION ISSUES, TRENDS, POLICIES, AND BEST PRACTICES FOR USE BY THE ORGANIZATION. THE ORGANIZATION ALSO HAS AN ESTABLISHED COMPENSATION POLICY FOR ALL OF ITS EMPLOYEES, WHICH SETS FORTH THE GENERAL PARAMETERS GOVERNING BIO'S COMPENSATION PRACTICES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART IX, LINE 11G EC EMERGING PRIORITIES 5,737,318. CONSULTANTS AND OTHER PROFESSIONAL FEES 1,997,572. ECONOMIC STUDIES 325,137. WORKPLAN OBJECTIVES 136,051. TEMPORARY HELP 133,692. EDUCATION 76,086. PROGRAM INITIATIVES 32,972. INTERNS 32,468. BIO-PAC ADMINISTRATIVE 30,783. RECRUITMENT 21,676. BUSINESS STRATEGIES 10,331. CEO DELEGATION EXPENSE 649. I&E INITIATIVES 350.